Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. reports developments in genomic testing for rare disease diagnosis, with recurring updates on ExomeDx™ and GenomeDx™ testing, exome and genome test volumes, revenue growth, and full-year outlooks. The company uses GeneDx Infinity™, a rare disease genomic dataset, to support clinical interpretation, AI-enabled variant analysis, and biopharma discovery.
Company news also covers research publications and medical-meeting abstracts, health economics studies involving whole exome and whole genome sequencing, sponsored genetic testing programs for suspected rare diseases, and partnerships intended to expand access to genomic diagnosis. Updates frequently connect clinical data, sequencing technology, and rare disease patient identification with the company's precision-medicine operating model.
GeneDx (Nasdaq: WGS) announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, from June 8-10, 2026. A fireside chat is scheduled for June 9, 2026, at 8:00 a.m. ET, with a live and archived webcast available on the GeneDx investor relations website.
GeneDx (Nasdaq: WGS) reported Q1 2026 revenue of $102.3M and exome/genome revenue $90.6M, with test volume of 27,488 (up 34% YoY). Adjusted gross margin was 69% and adjusted net loss was $8.2M. Cash and equivalents totaled $171.7M as of March 31, 2026.
The company updated full‑year 2026 guidance to $475–$490M revenue, at least 30% exome/genome volume growth, ~70% adjusted gross margin, and remains positive on adjusted net income for the year.
GeneDx (Nasdaq: WGS) will report first quarter 2026 financial results after market close on Monday, May 4, 2026. Management will host a conference call the same day at 4:30 p.m. Eastern Time to discuss financial and operating results.
Investors must register online to access the live call; a live and archived webcast will be available in the Events section of the GeneDx investor relations website.
GeneDx (Nasdaq: WGS) announced SAVES-Kids real-world HEOR findings showing up to 61% reduction in 12-month total healthcare costs for children with epilepsy after ExomeDx and GenomeDx testing, with average costs falling from $130,048 to $50,798 PPPY and average savings of ~$79,250.
The study reports broad cost reductions and fewer hospitalizations and ER visits across epilepsy and DD/ID cohorts, larger gains in Medicaid populations, and shifts toward increased outpatient and pharmacy use consistent with targeted care.
GeneDx (Nasdaq: WGS) and Zevra Therapeutics announced a Sponsored Genetic Testing Program to expand access to GeneDx’s ExomeDx test for U.S. patients with suspected Niemann-Pick disease type C (NPC). Eligible patients may receive testing at no charge, with results available in as little as three weeks.
De-identified data from the program will be added to GeneDx Infinity™, aiming to improve NPC diagnosis speed and support clinical decision-making as new therapies emerge. Zevra will provide financial support for the program.
GeneDx (Nasdaq: WGS) will present 18 abstracts at ACMG 2026 (March 12–13), highlighting sequencing innovations, AI-supported interpretation, and real-world impacts of earlier genomic diagnosis.
Presentations showcase GeneDx Infinity (more than a million exomes and genomes), AI tools to speed variant interpretation, a 51.4% diagnostic yield from >300,000 cases, and benchmarking of advanced sequencing methods.
GeneDx (Nasdaq: WGS) said company management will present at two investor conferences in March 2026: a fireside chat at TD Cowen on March 2, 2026 at 1:50 p.m. ET and a presentation at Barclays on March 11, 2026 at 3:00 p.m. ET.
Live and archived webcasts will be available in the Events section of the GeneDx investor relations website.
GeneDx (Nasdaq: WGS) reported Q4 2025 revenue of $121.0M (27% YoY; 37% ex-adjustment) and full-year 2025 revenue of $427.5M (41% YoY). Exome/genome revenue grew 32% in Q4 to $104.0M; volume rose 34% in Q4 to 27,761 results.
Adjusted gross margin was 71% in Q4 and full-year 2025. Adjusted net income was $4.4M in Q4 and $41.8M for FY2025. GeneDx reaffirmed 2026 guidance: $540–$555M revenue and 33–35% exome/genome growth.
Summary not available.
GeneDx (Nasdaq: WGS) announced that CEO Katherine Stueland was named to the TIME100 Health 2026 list, highlighting GeneDx’s role in rare disease genomics and precision medicine.
Key milestones cited include FDA Breakthrough Device designation for exome/genome testing, AAP guidance updating exome/genome as a first-tier test, and a 3.7% newborn screen positive rate in the GUARDIAN study.